Search Results for "Strattera"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Strattera. Results 1 to 2 of 2 total matches.
See also: atomoxetine
Clonidine Oral Suspension (Onyda XR) for ADHD
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024 (Issue 1718)
norepinephrine reuptake
inhibitors atomoxetine (Strattera, and generics)
and viloxazine (Qelbree), which ...
The FDA has approved Onyda XR (Tris), an extended-release
(ER) oral suspension formulation of the alpha2-adrenergic agonist clonidine, for use as monotherapy
or as an adjunct to stimulant therapy for treatment
of attention-deficit/hyperactivity disorder (ADHD) in
children ≥6 years old. Clonidine ER tablets have been
available for years for treatment of ADHD in children
6-17 years old.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):205-6 doi:10.58347/tml.2024.1718d | Show Introduction Hide Introduction
Viloxazine ER (Qelbree) for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
in the US for treatment of ADHD; atomoxetine
(Strattera, and generics) was approved in 2002.
STANDARD TREATMENT ...
The FDA has approved viloxazine extended-release
capsules (Qelbree – Supernus) for treatment of
attention-deficit/hyperactivity disorder (ADHD) in
children 6-17 years old. Viloxazine is the second
selective norepinephrine reuptake inhibitor to be
approved in the US for treatment of ADHD; atomoxetine
(Strattera, and generics) was approved in 2002.